Dendritic cells-derived extracellular vesicles in tumourigenesis: From biological roles to clinical implications

IF 10.1 1区医学 Q1 ONCOLOGY

Cancer letters Pub Date : 2025-09-06 DOI:10.1016/j.canlet.2025.218034

Qingning Chen , Weiyuan Wang , Xiaoyun He , Chunrong Wang , Hongbin Guo , Chunlin Ou

{"title":"Dendritic cells-derived extracellular vesicles in tumourigenesis: From biological roles to clinical implications","authors":"Qingning Chen , Weiyuan Wang , Xiaoyun He , Chunrong Wang , Hongbin Guo , Chunlin Ou","doi":"10.1016/j.canlet.2025.218034","DOIUrl":null,"url":null,"abstract":"<div><div>Dendritic cells (DCs) are the most powerful antigen-presenting cells (APCs) within the tumour microenvironment (TME), where they orchestrate T cell-mediated anti-tumour immunity and can also be reprogrammed to promote the progression of tumours in the TME. Extracellular vesicles (EVs) are very small and they are secreted by cells and wrapped in lipid bilayers that shuttle bioactive cargoes, including proteins, nucleic acids, and metabolites, to recipient cells, thereby influencing the progression of diseases, including cancer. DC-derived EVs (DC-EVs) play pivotal roles in the TME by mediating crosstalk with other immune and stromal cells to modulate inflammatory responses, angiogenesis, cell death, and immune evasion, thereby regulating the development and progression of tumours. In recent years, engineered DC-EVs have been widely used for cancer therapies, including cancer immunotherapy, chemotherapy, photodynamic therapy, and gene therapy. This review summarises the comprehensive roles of DC-EVs in tumourigenesis and the application of engineered DC-EVs in cancer therapy, potentially providing readers with a new theoretical basis for tumour-targeted therapy.</div></div>","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":"633 ","pages":"Article 218034"},"PeriodicalIF":10.1000,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer letters","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0304383525006044","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Dendritic cells (DCs) are the most powerful antigen-presenting cells (APCs) within the tumour microenvironment (TME), where they orchestrate T cell-mediated anti-tumour immunity and can also be reprogrammed to promote the progression of tumours in the TME. Extracellular vesicles (EVs) are very small and they are secreted by cells and wrapped in lipid bilayers that shuttle bioactive cargoes, including proteins, nucleic acids, and metabolites, to recipient cells, thereby influencing the progression of diseases, including cancer. DC-derived EVs (DC-EVs) play pivotal roles in the TME by mediating crosstalk with other immune and stromal cells to modulate inflammatory responses, angiogenesis, cell death, and immune evasion, thereby regulating the development and progression of tumours. In recent years, engineered DC-EVs have been widely used for cancer therapies, including cancer immunotherapy, chemotherapy, photodynamic therapy, and gene therapy. This review summarises the comprehensive roles of DC-EVs in tumourigenesis and the application of engineered DC-EVs in cancer therapy, potentially providing readers with a new theoretical basis for tumour-targeted therapy.

查看原文本刊更多论文

树突状细胞衍生的细胞外囊泡在肿瘤发生中的作用：从生物学作用到临床意义

树突状细胞（dc）是肿瘤微环境（TME）中最强大的抗原呈递细胞（apc），它们协调T细胞介导的抗肿瘤免疫，也可以被重新编程以促进肿瘤在TME中的进展。细胞外囊泡（EVs）非常小，由细胞分泌，包裹在脂质双层中，将生物活性物质（包括蛋白质、核酸和代谢物）运送到受体细胞，从而影响包括癌症在内的疾病的进展。dc - ev在TME中发挥关键作用，通过介导与其他免疫和基质细胞的串扰，调节炎症反应、血管生成、细胞死亡和免疫逃避，从而调节肿瘤的发生和进展。近年来，工程化dc - ev已广泛应用于癌症治疗，包括癌症免疫治疗、化疗、光动力治疗和基因治疗。本文综述了dc - ev在肿瘤发生中的综合作用以及工程化dc - ev在肿瘤治疗中的应用，以期为肿瘤靶向治疗提供新的理论依据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer letters 医学-肿瘤学

CiteScore

17.70

自引率

2.10%

发文量

427

审稿时长

15 days

期刊介绍： Cancer Letters is a reputable international journal that serves as a platform for significant and original contributions in cancer research. The journal welcomes both full-length articles and Mini Reviews in the wide-ranging field of basic and translational oncology. Furthermore, it frequently presents Special Issues that shed light on current and topical areas in cancer research. Cancer Letters is highly interested in various fundamental aspects that can cater to a diverse readership. These areas include the molecular genetics and cell biology of cancer, radiation biology, molecular pathology, hormones and cancer, viral oncology, metastasis, and chemoprevention. The journal actively focuses on experimental therapeutics, particularly the advancement of targeted therapies for personalized cancer medicine, such as metronomic chemotherapy. By publishing groundbreaking research and promoting advancements in cancer treatments, Cancer Letters aims to actively contribute to the fight against cancer and the improvement of patient outcomes.